HEALTHSTORY 591· JUNE 20, 2026

Daraxonrasib Doubles Average Survival in Pancreatic Cancer, UCLA-Led Trial Shows

A UCLA-co-led international study presented May 31 at the American Society of Clinical Oncology annual meeting in Chicago reported that pancreatic cancer patients treated with daraxonrasib survived an average of 13.2 months — nearly double

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 590Nuclear Bros: Silicon Valley's Young Founders Race to Restart American Atomic Power NEXT STORY 592 →U.S. Confirms Second Strike on Iran Targeting Air Defenses as Oil Prices Surge

Keep reading

More from the desk.

15HEALTH

More than 200 ADA members demand leadership resign after scientists expelled in New Orleans

Five researchers were removed from a major diabetes organization's annual scientific conference, a once-a-year gathering where clinicians present new findings and debate the direction of clinical practice, in New Orleans last month. More th

health2 MIN

35HEALTH

Drug spending is up. PhRMA wants journalists to frame it differently.

Prescription drug spending is rising, and the pharmaceutical industry's main lobbying organization is running a campaign to change how reporters describe it. Lobbying, at its most basic, means paid outreach

health2 MIN

45HEALTH

Rigel Pharmaceuticals names Alison Hannah chief medical officer

The person who sets a drug company's clinical strategy and oversees how patient trials are designed is called the chief medical officer. Rigel Pharmaceuticals has filled that seat, hiring Alison Hannah as executive vice president and chief

health1 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk